Exosens among the strongest declines on the SBF 120: stock falls 3%
The Bordeaux-based optoelectronics company is moving against the grain of a rising Paris market. The decline occurs after a positive session and leaves the stock near its long-term moving averages.
A decline of more than 3% that brings the stock below its long-term moving averages
Exosens shares fall 3.11% to €59.20 in trading, while the SBF 120 gains 0.66%. This decline ranks it among the index's steepest drops, behind Aperam and Schneider Electric. The stock thus drops below its 50-day moving average at €59.98 (difference of 1.30%) and below its 200-day moving average at €59.81 (difference of 1.02%), while remaining above its 20-day moving average at €58.87€.
Over the week, the value declines 1.17%, which contrasts with a gain of 35.62% over one year. Today's movement erases part of the ground regained on Monday, when the stock had advanced 2% at the top of the index.
The €63.40 zone remains the resistance threshold and €54.15 the support level
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In line with previous sessions, the price is evolving within a corridor bounded by a support at €54.15 and resistance at €63.40. The stock is positioned roughly midway between the two levels, having tested neither today. The RSI at 55 remains neutral and indicates neither overbought nor oversold conditions.
On the agenda, Exosens will publish its nine-month revenue on October 27. The group had raised its 2026 targets on September 17, with approximately 20% growth in revenue and approximately 25% growth in adjusted EBITDA, a revision that had propelled the stock to the top of the index that day.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
